Literature DB >> 15017524

Angiotensin II receptor type 1 expression in erythroid progenitors: Implications for the pathogenesis of postrenal transplant erythrocytosis.

Michal Mrug1, Bruce A Julian, Josef T Prchal.   

Abstract

Under normal physiological conditions red blood cell production is controlled primarily by erythropoietin, although multiple additional stimulatory factors are likely to be involved. One of these factors, angiotensin II, can modulate erythropoiesis directly via its type 1 receptor, as well as indirectly through multiple secondary mediators. We propose that angiotensin II exerts its stimulatory effect during the early stages of erythropoiesis, and that this effect serves as an important compensatory mechanism if erythropoietin production is chronically inadequate. We speculate that if this compensatory stimulation continues to be abnormally high after restoration of erythropoietin production following renal transplantation, erythrocytosis ensues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15017524     DOI: 10.1016/j.semnephrol.2003.11.006

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  3 in total

1.  Clinical and molecular characterization of a family with a dominant renin gene mutation and response to treatment with fludrocortisone.

Authors:  A J Bleyer; M Zivná; H Hulková; K Hodanová; P Vyletal; J Sikora; J Zivný; J Sovová; T C Hart; J N Adams; M Elleder; K Kapp; R Haws; L D Cornell; S Kmoch; P S Hart
Journal:  Clin Nephrol       Date:  2010-12       Impact factor: 0.975

2.  Erythropoiesis and Blood Pressure Are Regulated via AT1 Receptor by Distinctive Pathways.

Authors:  Hideki Kato; Junji Ishida; Taiji Matsusaka; Tomohiro Ishimaru; Keiji Tanimoto; Fumihiro Sugiyama; Ken-Ichi Yagami; Masaomi Nangaku; Akiyoshi Fukamizu
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

3.  Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study.

Authors:  E J F Santos; E V Hortegal; H O Serra; J S Lages; N Salgado-Filho; A M Dos Santos
Journal:  Braz J Med Biol Res       Date:  2018-05-07       Impact factor: 2.590

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.